1-10 of 10
Kevin C. Conlon
Close
Sort by
Journal Articles

Phase 1 Study of Subcutaneous Recombinant Human (rh) Interleukin-15 and Intravenous Alemtuzumab in Patients with Rrelapsed/Refractory T-Cell Lymphoma

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Albert, RN, Deborah Allen, RN, Thomas A. Waldmann, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–24.
https://doi.org/10.1182/blood-2020-142065
Published: 2020
Journal Articles

Phase 1 Trial of Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocytic Leukemia

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Jennifer Hsu, RN, Clare Sun, MD, Adrian Wiestner, MD PhD, Thomas A. Waldmann, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3052.
https://doi.org/10.1182/blood-2019-130807
Published: 2019
Journal Articles

Interleukin-15 (IL-5) in Combination with Avelumab in Relapsed/Refractory Mature T-Cell Malignancies

Milos D. Miljkovic, MDMSc, Kevin C Conlon, MD, Sigrid Dubois, PhD, Jennifer Hsu, RN, Jeffrey Schlom, PhD, James Gulley, MD PhD, Thomas A. Waldmann, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1558.
https://doi.org/10.1182/blood-2019-128945
Published: 2019
Journal Articles

Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockade

Daniel A. Rauch, Kevin C. Conlon, Murali Janakiram, Jonathan E. Brammer, John C. Harding, B. Hilda Ye, Xingxing Zang, Xiaoxin Ren, Sydney Olson, Xiaogang Cheng, Milos D. Miljkovic, Hemalatha Sundaramoorthi, Ancy Joseph, Zachary L. Skidmore, Obi Griffith, Malachi Griffith, Thomas A. Waldmann, Lee Ratner
Journal: Blood
Blood (2019) 134 (17): 1406–1414.
https://doi.org/10.1182/blood.2019002038
Published: 2019
Includes: Supplemental data
Journal Articles

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

Sarah Cooley, MD, Fiona He, MD BS, BA, Veronika Bachanova, MD PhD, Greg M Vercellotti, MD FACP, Todd E. DeFor, MS, Julie Curtsinger, Paul Alexander Robertson, MD, Kevin C Conlon, MD, Thomas A Waldmann, MD, David H. McKenna, MD, Bruce Blazar, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 2649.
https://doi.org/10.1182/blood.V130.Suppl_1.2649.2649
Published: 2017
Journal Articles

Blockade of IL-2 and IL-15 Gamma Chain Receptor Signaling Decreases Leukemic Cell Viability in T-Cell Large Granular Lymphocyte Leukemia and Adult T-Cell Leukemia

Tracy Tiffany Wang, BS, Jun Yang, MD, Yong Zhang, PhD, Meili Zhang, PhD, Kevin C Conlon, MD, Yutaka Tagaya, B.M., PhD, Thomas L Olson, PhD, David J Feith, PhD, Nazli Azimi, Pharm.D., PhD, Thomas A. Waldmann, MD, Thomas P Loughran, Jr., MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3585.
https://doi.org/10.1182/blood.V130.Suppl_1.3585.3585
Published: 2017
Journal Articles

Transient Inhibition of the JAK1/3-STAT5 Pathway By Ruxolitinib Is Insufficient to Produce Clinical Benefit in Patients with Indolent Adult T-Cell Leukemia

Sigrid Dubois, PhD, Milos D. Miljkovic, MD, Thomas Fleisher, Jennifer Hsu, RN, Thomas A Waldmann, MD, Kevin C Conlon, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3840.
https://doi.org/10.1182/blood.V130.Suppl_1.3840.3840
Published: 2017
Journal Articles

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

Jing Chen, Cynthia A. Pise-Masison, Joanna H. Shih, John C. Morris, John E. Janik, Kevin C. Conlon, Anne Keating, Thomas A. Waldmann
Journal: Blood
Blood (2013) 121 (11): 2029–2037.
https://doi.org/10.1182/blood-2012-05-427773
Published: 2013
Includes: Supplemental data
Journal Articles

Phase 1 trial of IL-15 trans presentation blockade using humanized Mik-Beta-1 mAb in patients with T-cell large granular lymphocytic leukemia

Clinical Trials & Observations
Thomas A. Waldmann, Kevin C. Conlon, Donn M. Stewart, TatYana A. Worthy, John E. Janik, Thomas A. Fleisher, Paul S. Albert, William D. Figg, Shawn D. Spencer, Mark Raffeld, Jean R. Decker, Carolyn K. Goldman, Bonita R. Bryant, Michael N. Petrus, Stephen P. Creekmore, John C. Morris
Journal: Blood
Blood (2013) 121 (3): 476–484.
https://doi.org/10.1182/blood-2012-08-450585
Published: 2013
Includes: Supplemental data
Journal Articles

A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma

Clinical Trials & Observations
John E. Janik, Langdon L. Miller, Edward L. Korn, Diane Stevens, Brendan D. Curti, John W. Smith, II, Mario Sznol, Kevin C. Conlon, William Sharfman, Walter J. Urba, Barry L. Gause, Dan L. Longo
Journal: Blood
Blood (2001) 97 (7): 1942–1946.
https://doi.org/10.1182/blood.V97.7.1942
Published: 2001